India’s Pharmaceutical Exports Fuel West Africa’s Opioid Crisis
Over 320 million synthetic opioid tablets flooded fragmented supply chains across Sierra Leone, Ghana, and Nigeria, exposing systemic failures in global drug governance and regulatory arbitrage at scale.
India exported more than 1,400 consignments of tapentadol worth approximately $130 million to West African countries between 2023 and 2025, despite only two Indian firms holding licenses to manufacture the synthetic opioid for export. The 381% increase from $27 million (2020-2022) to $130 million (2023-2025) represents not a legitimate pharmaceutical expansion but a regulatory collapse, according to France 24 reporting published this week.
The crisis has transformed India’s reputation as the “pharmacy of the world” into a geopolitical liability. Over 320 million synthetic opioid tablets entered West Africa in three years, per Bellingcat analysis of trade data. More than 50% of high-dose tapentadol pills exported exceeded 200mg—levels not approved for use in India itself. This is regulatory arbitrage weaponized: Indian manufacturers produce formulations deemed unsafe domestically, then ship them to jurisdictions with weaker enforcement.
$27M
$130M
+381%
2
60+
The Regulatory Black Hole
India’s Central Drugs Standard Control Organisation (CDSCO) operates without legal authority to verify the legitimacy of foreign importers or maintain a central database of licensed exporters across the country’s 28 states. “There is no regulatory framework which checks a genuine importer and counterfeit importer between countries,” public health activist Dinesh Thakur told Newslaundry. “CDSCO has no law or regulations that allows one to check whether the importer is a legitimate entity or not.”
This vacuum enabled 60+ suppliers to export tapentadol since 2023, though only two held manufacturing licenses. The top three exporters—Syncom Formulations, Puizer Pharmaceuticals, and Twin Impex—accounted for half of all shipments analyzed. One firm, Careium Pharmaceuticals, grew revenue from $127,000 in 2021 to $40 crore ($4.8 million) in 2024-2025 by shipping $9.78 million worth of high-dose tapentadol to Ghana and Benin alone.
“This is very harmful for their health—but nowadays, this is business.”
— Vinod Sharma, Director, Aveo Pharmaceuticals
Aveo Pharmaceuticals, a Mumbai-based manufacturer, produced unlicensed tapentadol-carisoprodol combinations marketed as “Tafrodol” and exported millions of pills to West Africa before operations were suspended in February 2025 following a BBC investigation. India’s Drugs Controller General banned the manufacture and export of such combinations only after the exposé, per The Lancet Global Health.
West Africa’s Cascading Crisis
Nigeria has over 4 million opioid users among its 225 million population, according to Deccan Herald. The country’s drug regulator NAFDAC reports that 70% of consumed drugs are foreign imports, with approximately 50% counterfeit. India and China are the biggest sources of illicit medical products entering the region, per September 2023 ECOWAS research.
The human toll extends beyond opioids. Sub-Saharan Africa records 267,000 deaths annually from counterfeit or substandard antimalarial drugs, and 169,271 from fake antibiotics for pediatric pneumonia, according to a 2023 UNODC threat assessment. Substandard and falsified medicines prevalence averages 22.6% across Africa, with Ghana and Togo reaching 75%, per a 2024 systematic review.
The World Health Organisation reports that one in ten medicines in low and middle-income countries is substandard or counterfeit, with 42% of substandard medicine reports from 2013-2017 originating in Africa. India has not applied for WHO Global Benchmarking Tool evaluation of its medicines regulation—only vaccine regulation was benchmarked in 2017. This leaves African regulators unable to verify the quality standards of Indian pharmaceutical imports through WHO-validated systems, per Pulitzer Center investigation.
Price Arbitrage and Currency Dynamics
Indian generic pharmaceuticals typically cost 30-50% less than Western equivalents, making them attractive to cash-strapped health systems. India’s pharmaceutical exports to Africa represent approximately 20% of the country’s $30.4 billion total pharma exports in FY25 (April 2024 – March 2025), according to Indian export data. This price differential creates structural incentives for gray-market operators.
Weak customs enforcement and porous borders compound the problem. Yearly tramadol seizures in sub-Saharan Africa increased from 300kg to over 3 tons by 2018, per D+C Development + Cooperation reporting on pharmaceutical trafficking routes. The global pharmaceutical trafficking market is estimated at $200 billion annually.
- No central licensing database across India’s 28 states enables unlicensed manufacturers to operate
- CDSCO lacks legal authority to verify foreign importer legitimacy
- Indian manufacturers produce formulations (200mg+ tapentadol) not approved domestically
- West African nations have limited pharmaceutical testing infrastructure and customs capacity
- Price differential (30-50% cheaper than Western generics) drives demand despite quality concerns
- WHO has not benchmarked India’s medicines regulation, leaving African regulators without verification mechanism
Policy Paralysis and Enforcement Gaps
The February 2025 DCGI ban on tapentadol-carisoprodol combinations represents reactive rather than systemic reform. “The persistent demand for opioids in the region, coupled with weak regulatory enforcement and porous borders, increases the likelihood that traffickers will seek alternative sources of supply,” The Lancet Global Health warned in June 2025 analysis.
Nigeria’s drug regulator NAFDAC issued a public alert in May 2025 on illegal opioid exports, but enforcement remains constrained by resource limitations and jurisdictional boundaries. “If you don’t get punished for a crime, you will do it again,” Akinbode Oluwafemi of Corporate Accountability and Public Participation Africa told investigators.
Lawyer Prashant Reddy articulated the underlying logic: “India exports lower quality drugs to Africa because they know regulatory standards there are lower,” he told CIDRAP. This represents calculated exploitation of governance asymmetries rather than market failure.
Geopolitical Implications
The crisis exposes blind spots in India-West Africa relations at a moment when New Delhi seeks to deepen commercial and diplomatic ties across the continent. India’s pharmaceutical sector has been a soft-power asset, positioning the country as a reliable supplier to the Global South. The opioid pipeline threatens this narrative.
It also reveals how colonial-era trade routes persist in contemporary supply chains. The concentration of exports to former British colonies (Sierra Leone, Ghana, Nigeria) and former French territories (Togo, Benin, Senegal) suggests that historical commercial relationships shape modern trafficking patterns, per Global Initiative Against Transnational Organized Crime mapping published in March 2026.
What to Watch
Whether India establishes a centralized export licensing database with real-time verification of foreign importers. Current CDSCO authority does not extend to vetting destination-country recipients, creating a permanent accountability gap.
How West African nations respond to the crisis beyond individual product bans. Ghana and Nigeria have announced enhanced customs screening, but implementation requires technical capacity and resources neither country currently possesses at scale.
The trajectory of synthetic opioid markets as regulatory pressure shifts supply chains. The Lancet Global Health predicted that demand would drive traffickers toward alternative sources—early evidence suggests nitazenes and related synthetics are entering regional markets through Chinese suppliers, per the Global Initiative Against Transnational Organized Crime.
Whether the WHO revises its approach to India’s pharmaceutical regulation. The absence of Global Benchmarking Tool evaluation for medicines (versus vaccines) leaves a critical blind spot in global drug governance. African regulators have no validated mechanism to verify quality standards of Indian imports.
India’s diplomatic response as the crisis gains international attention. New Delhi has historically defended its pharmaceutical sector as essential to global health access. The opioid pipeline forces a reckoning between that narrative and the documented harms of regulatory arbitrage at scale.